MedPath

Study on the effect of traditional Chinese medicine combined with multi-pathway intervention in patients with renal Yin deficiency, liver stagnation and blood stasis type to re-IVF-ET antagonist scheme for assisted pregnancy

Phase 1
Recruiting
Conditions
infertility
Registration Number
ITMCTR2000004113
Lead Sponsor
Affiliated Hospital of Chengdu University of TCM
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Female
Target Recruitment
Not specified
Inclusion Criteria

(1) Second ART treatment cycle, previous IVF cycle <= 2 times;
(2) Age >= 35 years old, AMH >= 1.2ng/ml, AFC >= 5, the number of eggs obtained in the previous IVF 1~9; Or age < 35, AMH < 1.2ng/ml (groups 2 and 3 meeting the classification criteria of Poseidon population);
(3) With INDICATIONS for IVF/ICSI, excluding contraindications;
(4) The patient has no blastocyst or frozen embryo;
(5) All patients were treated with antagonist regimen for drainage promotion;
(6) Those who meet the standard of syndrome differentiation of kidney Yin deficiency, liver stagnation and blood stasis;
(7) Knowing and voluntarily signing the informed consent. Note: only those who conform to the above 7 items can be included.

Exclusion Criteria

(1) Study on the Efficacy of Traditional Chinese medicine combined with multi-pathway intervention in patients with re-IVF-ET antagonist with Kidney Yin deficiency, Liver stagnation and blood stasis;
(2) Patients with drug allergy or allergic constitution;
(3) Patients with severe primary diseases such as cardiovascular, liver, kidney and hematopoietic system, or mental diseases;
(4) Patients with acute infectious diseases or physical organic diseases;
(5) Genital deformity, inflammation and tumor of the reproductive system are confirmed by examination;
(6) having a genetic disease that is not suitable for reproduction as stipulated in the Law on Maternal and Child Health care;
(7) Serious bad habits such as drug abuse;
(8) Exposure to teratogenic radiation, poisons, and drugs at the active stage.
Note: Any of the above 8 items shall be excluded.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
atural pregnancy rate;Basal sex hormone levels;TCM syndrome integral;
Secondary Outcome Measures
NameTimeMethod
Âİ Copyright 2025. All Rights Reserved by MedPath